SCHEMBL22801565

SCHEMBL22801565

COC(=O)c1cccc(-c2nn(C(=O)OC(C)(C)C)c3ccccc23)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 1/20 0.62
ELANE P08246 5/20 0.46
PLAU P00749 3/20 0.46
F2 P00734 2/20 0.46
RORC P51449 2/20 0.43
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41
GABRA3 P34903 1/20 0.41
GPR84 Q9NQS5 2/20 0.40
NEK1 Q96PY6 1/20 0.40
PDE5A O76074 1/20 0.40
AXL P30530 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6371415 0.84 ELANE (0.53) MAP2K4ELANEPLAUF2ALDH1A1
SCHEMBL6369498 0.82 MAP2K4 (0.49) MAP2K4RORCALDH1A1KMT2APDE5A
SCHEMBL17829690 0.81 MAP2K4 (0.71) MAP2K4RORCALDH1A1KDM4ELMNA
SCHEMBL22801612 0.79 MAP2K4 (0.77) MAP2K4ELANEPLAUF2
SCHEMBL29057628 0.77 MAP2K4 (0.50) MAP2K4RORCALDH1A1HPGDSMN1; SMN2
SCHEMBL22801731 0.76 MAP2K4 (1.00) MAP2K4PLAU
SCHEMBL22801648 0.75 MAP2K4 (0.52) MAP2K4ALDH1A1HPGDSMN1; SMN2HTT
SCHEMBL22801748 0.75 MAP2K4 (0.52) MAP2K4RORCALDH1A1HPGDSMN1; SMN2
SCHEMBL1513042 0.75 MAP2K4 (0.48) MAP2K4RORCALDH1A1HPGDSMN1; SMN2
SCHEMBL1513019 0.75 MAP2K4 (0.63) MAP2K4RORCALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11370770-B2 3-arylindazoles as selective MEK4 inhibitors NORTHWESTERN UNIVERSITY (US) 2022-06-28 US disclosed
US-20200399241-A1 3-ARYLINDAZOLES AS SELECTIVE MEK4 INHIBITORS NORTHWESTERN UNIVERSITY (US) 2020-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399241-A1 3-ARYLINDAZOLES AS SELECTIVE MEK4 INHIBITORS MAP4K3, MAPK4, MAP3K4 MAP2K4 39/4885ELANE 2771/4885PLAU 4659/4885
US-11370770-B2 3-arylindazoles as selective MEK4 inhibitors MAP4K3, MAPK4, MAP3K4 MAP2K4 39/4885ELANE 2771/4885PLAU 4659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.